| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |